CAR-T Hematology Deal Benchmarks
Market Analysis
CAR-T cell therapy in hematologic malignancies remains the most clinically validated application of engineered cell therapy, with six approved products generating $5B+ in combined annual revenue. Phase 1 CAR-T hematology deals carry a median total deal value of $2.1B, with upfront payments of $247M. The validated clinical paradigm and established manufacturing infrastructure support deal premiums even at early clinical stages.
Milestone structures in hematology CAR-T deals reflect the established clinical pathway. Development milestones average $615M, with key gates at Phase 1 dose selection, pivotal trial initiation, and BLA filing. Regulatory milestones of $506M and commercial milestones of $687M reward successful market entry and indication expansion.
Royalty rates for hematology CAR-T deals range from 5.7% to 12.6%, reflecting the unique manufacturing economics of autologous cell therapy. Allogeneic and in-vivo CAR-T approaches that address scalability limitations can command higher total deal values. Next-generation targets beyond CD19 and BCMA (GPRC5D, CD70, CD22) are driving the next wave of licensing activity.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for hematology CAR-T licensing?
How do autologous vs. allogeneic CAR-T deal terms differ?
Which CAR-T targets are most actively licensed in hematology?
What manufacturing factors affect CAR-T deal valuations?
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating